This is important... and often overlooked.
In orthopedics, we love to talk about clinical data, disruptive tech, and market opportunity. But if you’re considering joining a new orthopedic company—whether it’s an early-stage startup or a mid-cap player—there is one metric that matters above all else: its true financial health.
Joining a company without auditing its balance sheet is a high-stakes gamble. You can have brilliant technology and a powerhouse sales team, but if the company is running on fumes, your career will take the hit.
The Reality Check Across Public Orthopedics
Look at the current landscape across public medtech. While industry giants like Stryker or Globus operate with massive cash reserves, dozens of small-to-mid-cap orthopedics are fighting for survival:
Severe Distress: Companies like Aclarion (ACON) and Bone Biologics (BBLG) burn through millions quarterly while generating under $100K in revenue, relying entirely on extreme equity dilution just to keep clinical trials alive.
Capital Squeezes: Treace Medical (TMCI) and Bioventus (BVS) have faced severe margin compression or heavy debt burdens, forcing massive debt financing or asset sales just to maintain liqui...
